Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Wave Life Sciences Ltd. Director's Dealing 2024

Feb 8, 2024

31900_dirs_2024-02-07_20dda9c3-6868-4873-bf1a-ad5bb5bcde88.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2024-02-05

Reporting Person: Vargeese Chandra (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-05 Share Option (right to buy) $3.87 A 361700 Acquired 2034-02-05 Ordinary Shares (361700) Direct

Footnotes

F1: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.